ASBMR is taking place
ASBMR presentation details
Title: 'TYRA-300 Demonstrates Significant Increases in Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal Dysplasia'
Presentation Number: 1077
Session: Oral Presentations:
Presentation Date/Time:
TYRA Presenter:
ASHG presentation details
Title: 'TYRA-300 Demonstrates Significant Increases in Growth and Bone Length in a Mouse Model of FGFR3-Related Skeletal Dysplasia'
Session: Oral Presentations: Precision prescription: The therapeutic potential of ASOs and small molecules for genetic disorders
Presentation Date/Time:
TYRA Presenter:
About TYRA-300
TYRA-300 is the Company's lead precision medicine program stemming from its in-house SNAP platform. TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for the treatment of cancer and skeletal dysplasias including achondroplasia. TYRA-300 is being evaluated in a multi-center, open label Phase 1/2 clinical study, SURF301 (Study in Untreated and Resistant FGFR3+ Advanced Solid Tumors). SURF301 (NCT05544552) was designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300. SURF301 is currently enrolling adults with advanced urothelial carcinoma and other solid tumors with FGFR3 gene alterations. In skeletal dysplasias, TYRA-300 has demonstrated positive preclinical results and the Company expects to submit an IND for the initiation of a Phase 2 clinical study in pediatric achondroplasia in 2024.
About
Contact:
Email: aconrad@tyra.bio
(C) 2023 Electronic News Publishing, source